Several possible studies
Story checked
Hair loss with GLP-1 drugs is rare, but real, studies find | Reuters (opens in a new tab)
reuters.com · 2026-07-22
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Hair loss with GLP-1 drugs is rare, but real, studies find | Reuters
reuters.com · 2026-07-22
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Source layer
The 3 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- The study this story reportspresented as the new finding
https://www.bmj.com/content/394/bmj-2026-100077
- Points somewhere elsepresented as the new finding
https://www.jaad.org/article/S0190-9622(26)00248-3/fulltext
- Points somewhere elsepresented as the new finding
https://www.preprints.org/manuscript/202607.1370
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedThe risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes is low, but new studies suggest it is higher than with other diabetes drugs.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 6Not checkedAt two or more years after starting treatment, the odds of a new diagnosis of alopecia in GLP-1 users were 37% higher than in users of SGLT-2 drugs and 68% higher versus DPP-4 drugs, according to researchers at the University of Pennsylvania in The BMJ.View evidenceHide evidence
As stated37% higher vs SGLT-2 drugs; 68% higher vs DPP-4 drugs
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 6Not checkedActual rates of alopecia were low, ranging from roughly 3 to 9 per 1,000 people per year, with between 11,000 and 15,000 people in each drug-class group.View evidenceHide evidence
As statedroughly 3 to 9 per 1,000 people per year
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 6Not checkedA separate recent study in the Journal of the American Academy of Dermatology with more than 1 million participants worldwide found significantly higher risks of various subtypes of alopecia with GLP-1 drugs than with metformin.View evidenceHide evidence
As statedmore than 1 million participants worldwide
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 6Not checkedA third new study suggests GLP-1 users face higher alopecia odds with tirzepatide than with semaglutide, with 4.24% versus 3.33% overall and 5.44% versus 3.63% among female users.View evidenceHide evidence
As stated4.24% vs 3.33% overall; 5.44% vs 3.63% in female users
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 6 of 6Not checkedAll three papers say that hair loss often accompanies weight loss and is often reversible, but the nference study said the higher risk with tirzepatide persisted regardless of weight loss or dose and may point to other explanations such as thyroid disease or other endocrine disorders.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation.
BMJ (Clinical Research Ed.) · 2026 · PubMed, Europe PMC
Review for "Comparative Effectiveness of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and DPP-4 Inhibitors on Liver Outcomes in MASLD: A Retrospective Cohort Study"
2025 · Crossref
Adipocytes as a Mechanistic Link Between Incretin-Based Therapies and Hair Loss.
2026 · Europe PMC
Review for "Comparative Effectiveness of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and DPP-4 Inhibitors on Liver Outcomes in MASLD: A Retrospective Cohort Study"
2026 · Crossref
GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives.
2026 · Europe PMC